Published and not fully published double-blind, randomised, controlled trials with oral naratriptan in the treatment of migraine: a review based on the GSK Trial Register

@inproceedings{TfeltHansen2011PublishedAN,
  title={Published and not fully published double-blind, randomised, controlled trials with oral naratriptan in the treatment of migraine: a review based on the GSK Trial Register},
  author={Peer Carsten Tfelt-Hansen},
  booktitle={The Journal of Headache and Pain},
  year={2011}
}
Naratriptan 2.5 mg is now an over-the-counter drug in Germany. This should increase the interest in drug. The GSK Trial Register was searched for published and unpublished double-blind, randomised, controlled trials (RCTs) concerning the use of naratriptan in migraine. Only 7 of 17 RCTs are published in full. Naratriptan 2.5 mg is superior to placebo for acute migraine treatment in 6 RCTs, but inferior to sumatriptan 100 mg and rizatriptan 10 mg in one RCT each. This dose of naratriptan has no… CONTINUE READING
4 Citations
23 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 23 references

Naratriptan: the gentle triptan

  • R Salonen
  • 2001
Highly Influential
4 Excerpts

Triptans, 5HT1B/1D agonists in the acute treatment of migraine

  • PR Saxena, P Tfelt-Hansen
  • KMA (eds) The headaches,
  • 2006
Highly Influential
4 Excerpts

Efficacy and tolerability of naratriptan tablets (0.1–2.5 mg) in the acute treatment of migraine

  • D Bates
  • Eur J Neurol
  • 1998
Highly Influential
8 Excerpts

Similar Papers

Loading similar papers…